# A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

> **NCT06503731** · PHASE2 · RECRUITING · sponsor: **argenx** · enrollment: 30 (estimated)

## Conditions studied

- Antibody-mediated Rejection

## Interventions

- **COMBINATION_PRODUCT:** Efgartigimod PH20 SC - prefilled syringe
- **OTHER:** Placebo PH20 SC - prefilled syringe

## Key facts

- **NCT ID:** NCT06503731
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06503731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06503731, "A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06503731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*